Reviews/Chronic Spontaneous Urticaria Treatment/Type IIb autoimmune chronic spontaneous urticaria and omalizumab
Biomarkers · CSU-BM-01 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
The claim is that a specific autoimmune subtype of chronic hives (type IIb) responds less well to omalizumab. No study in this corpus that actually tested patients and measured their response used that strict definition. The studies that did test patients point in both directions: one found that patients whose blood test for autoreactivity was negative responded much better [15] and that low baseline IgE went with nonresponse [1], while another found autoimmune patients responded well to the drug [3] and a dedicated autoimmune test showed no link to response at all [12]. Every source that states the claim outright is a review article, which the panel's rules exclude from carrying the verdict [8][10][13][17]. Because the direct support rests on indirect markers and is offset by studies pointing the other way, the panel landed in the middle.
Among the patient-level studies here, the evidence is split. Low baseline IgE was associated with nonresponse to omalizumab [1], and patients with a positive histamine-release (autoreactive) test responded far worse, with an odds ratio of 9.07 favouring the histamine-release-negative group [15]. Pulling the other way, twelve patients with chronic autoimmune urticaria defined by anti-FcεRIα showed significant symptom improvement on omalizumab [3], and a study using an autoimmune mast-cell activation test found no difference between test result and response, with 84% of patients responding [12]. The review articles that state the claim directly describe type IIb by strict triple-positivity criteria present in under 10% of patients [8], but none of these are patient-level tests of efficacy. The contested point: The division is whether indirect autoimmune markers (low IgE, a positive histamine-release test) can stand in for the strict type IIb definition, and whether the two contradicting studies [3][12] cancel the supporting ones [1][15]. The surrogate markers overlap with type IIb but are not the same construct, so the direct claim is never tested head-on by an eligible study.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No eligible primary study tests the strict type IIb definition (triple positivity: autologous serum skin test + IgG immunoassay + basophil activation test) against omalizumab efficacy. The direct assertion exists only in study-type-excluded reviews [8][10][13][17]; primary evidence uses surrogates (low IgE [1][14], positive histamine-release [15], aiMAT [12]) that overlap with but are not equivalent to type IIb.
Primary evidence is directionally mixed, not confirmatory: autoimmune (anti-FcεRIα) patients responded to omalizumab [3], and the autoimmune mast-cell activation test showed no association with response [12]. These primary results actively contradict the claim.
Where it remains uncertain. Every source asserting the type IIb claim outright is a review excluded from the verdict [8][10][13][17], leaving only surrogate markers that overlap with, but do not equal, type IIb.
Aleatory
Response is partial and graded even within marker-defined groups, e.g. four of twelve autoimmune patients improved but kept urticaria and one did not respond [3].
Epistemic
No patient-level study classifies by triple positivity and measures efficacy; the strict definition appears only in excluded reviews [8][17].
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Low baseline IgE (a defining type IIb feature) predicts omalizumab nonresponse; supports the claim via surrogate.
“Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).”
Panel auditInternal validity: medium · scope of inference: Association between baseline and on-treatment total IgE and omalizumab response in antihistamine-refractory CSU.Key limitations: no type IIb classification · IgE used as proxy not endotype · single cohort
Omalizumab was efficacious in chronic autoimmune urticaria patients; counters the claim's direction (small n=12).
“Mean UAS declined significantly from baseline to the final 4 weeks of omalizumab treatment (7.50 +/- 1.78 to 2.66 +/- 3.31, -4.84 +/- 2.86, P = .0002). Seven patients achieved complete symptom resolution.”
Panel auditInternal validity: low · scope of inference: Whether omalizumab reduces symptoms in antihistamine-resistant chronic autoimmune urticaria.Key limitations: tiny sample · no comparator endotype · proof-of-concept
An autoimmune mast-cell activation marker showed no association with omalizumab response; directly counters the claim.
“Overall, 36 out of 43 (84%) patients responded to omalizumab, and 7 (16%) were nonresponders. We found no differences between LAD2 CD63 response and response to omalizumab.”
Panel auditInternal validity: low · scope of inference: Diagnostic performance of an autoimmune mast cell activation test in CSU and its relation to omalizumab response.Key limitations: few nonresponders · aiMAT not strict type IIb criteria · underpowered for prediction
Supplied abstract text is internally contradictory; weighted only as neutral/uncertain, not as support.
“No differences were found between the three responder groups (CR, PR, and NR)”
Panel auditInternal validity: low · scope of inference: Relationship between total IgE level and omalizumab response categories in symptomatic chronic urticaria.Key limitations: no endotype classification · heterogeneous assays · garbled abstract text
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Mixed primary evidence restricted to surrogate markers, with no strict type IIb efficacy data, places the exact claim at the lower edge of assessable confidence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No strict type IIb efficacy study. The claim names type IIb, but no patient-level study here classifies by triple positivity (autologous serum skin test + IgG immunoassay + basophil activation test) and measures omalizumab response. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort enrolling antihistamine-refractory CSU patients, classifying each by strict triple-positivity criteria, and comparing omalizumab response rates against non-type-IIb patients.
Open question: Does strict type IIb classification predict a lower omalizumab response rate than non-type-IIb CSU? Why it is still open: No eligible primary study in the corpus applied the strict triple-positivity definition to measure efficacy; the direct assertion appears only in excluded reviews [8][17].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19